沃顿胶间充质干细胞在严重肢体缺血中的应用
本文综述沃顿胶间充质干细胞(WJ-MSCs)治疗严重肢体缺血(CLI)的分子与细胞机制。WJ-MSCs 来源丰富、易于分离且无伦理争议,近期初步研究提示其对缺乏替代治疗方案的终末期外周动脉疾病(PAD)患者可能有效,但需随机对照试验全面评估安全性与有效性。
要点
- WJ-MSCs 可能为终末期 PAD 患者提供新的治疗策略
- WJ-MSCs 来源丰富、易分离且无伦理争议
- 需随机、适当把握度的临床试验评估其安全性与有效性
核心结论
- WJ-MSCs 可能成为终末期严重肢体缺血的新治疗策略,但需随机对照试验验证。
研究设计与样本
- 综述,总结 WJ-MSCs 在严重肢体缺血中作用的分子与细胞机制。
主要发现
- 近期初步研究提示 WJ-MSCs 对缺乏替代治疗方案的终末期 PAD 患者有效。
- WJ-MSCs 的丰富性、易分离及无伦理争议有利于其临床使用。
- WJ-MSCs 的解剖来源异质性被确定为关键疗效变量。
- 提出 WJ-MSCs 与血运重建联合治疗的策略。
临床怎么用
- WJ-MSCs 可能作为终末期 PAD 患者缺乏替代治疗方案时的选择。
- 可考虑 WJ-MSCs 与血运重建联合治疗。
局限性
- 需随机、适当把握度的临床试验全面评估 WJ-MSCs 的安全性与有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral artery disease (PAD) is a chronic vascular condition, and patients in the advanced stages typically do not respond favorably to interventional or surgical approaches. Recent advancements in Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) fundamental research have produced promising data in the context of PAD management. As recent pilot studies have suggested WJ-MSCs efficacy in patients with end-stage PAD who lack alternative treatment option, WJ-MSCs may offer a novel therapeutic strategy for managing end-stage PAD. The abundance, ease of isolation, and absence of ethical concerns associated with WJ-MSCs facilitate their potential clinical use. However, randomized, appropriately powered clinical trials are necessary to comprehensively assess their safety and effectiveness. This review aims to summarize the molecular and cellular mechanisms underlying the emerging role of WJ-MSCs in critical limb ischemia.Clinical ImpactThis review establishes Wharton's Jelly MSCs (WJ-MSCs) as a paradigm-shifting therapy for end-stage critical limb ischemia (CLI).This review pioneers a translational roadmap for WJ-MSCs in CLI by integrating molecular mechanisms, preclinical models, and clinical outcomes. It uniquely identifies anatomic sourcing heterogeneity as a critical efficacy variable and proposes combination therapy with revascularization.
引用
- Liang H, Zhao B, Ren Y, et al. Application of Wharton's Jelly Mesenchymal Stem Cells in Critical Limb Ischemia. J Endovasc Ther. 2025. PMID: 40847921. doi:10.1177/15266028251361770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。